Viatris Inc. filings document the reporting record of a global healthcare company whose common stock trades on Nasdaq under VTRS. Form 8-K disclosures cover operating results, guidance and material events, including leadership transitions, restructuring actions from an enterprise-wide strategic review, bylaw amendments and shareholder-meeting matters.
Proxy statements describe board oversight, executive compensation, shareholder voting proposals, director nominations and governance practices. The filings also provide formal records for Viatris' capital return activity, strategic priorities, pipeline and product references, and the company's history as the combination of Mylan with Pfizer's Upjohn business.
State Street Corporation reports beneficial ownership of 55,292,535 shares of Viatris common stock, representing 4.7% of the class. The filing shows shared voting power of 35,527,445 shares and shared dispositive power of 55,287,700 shares, with no sole voting or dispositive power reported.
The statement clarifies these holdings are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Multiple State Street Global Advisors affiliates are identified as the relevant subsidiaries involved in the holdings.